Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Leukemia 2 Hematologic Neoplasms 2 Thyroid Nodule 1 Thyroid Neoplasms 1 Thyroid Diseases 1 Paraproteinemias 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Myeloid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Cardiotoxicity 1 Breast Neoplasms 1

Interventions

Carboplatin 177 Radiotherapy 139 Cisplatin 110 Pemetrexed 102 Docetaxel 93 Paclitaxel 92 Gemcitabine 78 Erlotinib Hydrochloride 73 Magnetic Resonance Spectroscopy 72 Radiosurgery 67 Bevacizumab 65 pembrolizumab 64 Etoposide 60 Blood Specimen Collection 60 durvalumab 53 Specimen Handling 48 Nivolumab 48 Surveys and Questionnaires 47 Drug Therapy 41 Standard of Care 35 Radiation 33 osimertinib 32 atezolizumab 32 Surgical Procedures, Operative 30 Topotecan 29 Irinotecan 29 Gefitinib 29 Educational Status 29 Early Intervention, Educational 29 Biopsy 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lung Neoplasms × Blood Cell Count × Clear all

NCT03749512 2018-11-21

NLCR in Prediction of the Grade of Lung Tumor.

Medical University of Silesia

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡